Caricamento...
Bispecific antibodies in cancer immunotherapy
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeu...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publishing
2018-02-01
|
| Serie: | Therapeutic Advances in Vaccines and Immunotherapy |
| Accesso online: | https://doi.org/10.1177/2515135518763280 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|